Halozyme Therapeutics, Inc. to Post FY2026 Earnings of $5.16 Per Share, Zacks Research Forecasts (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Research analysts at Zacks Research upped their FY2026 EPS estimates for shares of Halozyme Therapeutics in a report issued on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings of $5.16 per share for the year, up from their previous estimate of $5.08. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.45 per share.

Several other research analysts have also recently weighed in on the stock. TD Cowen assumed coverage on shares of Halozyme Therapeutics in a research report on Thursday, February 29th. They set an “outperform” rating and a $54.00 price target on the stock. Benchmark reiterated a “buy” rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. JMP Securities reiterated a “market outperform” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, April 17th. Finally, The Goldman Sachs Group cut their price target on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research note on Thursday, January 18th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $53.29.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $38.46 on Wednesday. Halozyme Therapeutics has a 52-week low of $29.85 and a 52-week high of $45.00. The firm has a market capitalization of $4.89 billion, a price-to-earnings ratio of 18.23, a PEG ratio of 0.45 and a beta of 1.25. The company has a fifty day simple moving average of $39.79 and a 200-day simple moving average of $37.80. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The business had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total transaction of $384,900.00. Following the sale, the senior vice president now directly owns 168,176 shares in the company, valued at $6,473,094.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 30,000 shares of company stock worth $1,196,800. Company insiders own 2.40% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

A number of large investors have recently made changes to their positions in HALO. Vanguard Group Inc. increased its stake in Halozyme Therapeutics by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 13,259,514 shares of the biopharmaceutical company’s stock valued at $490,072,000 after purchasing an additional 152,870 shares during the last quarter. Artisan Partners Limited Partnership increased its stake in Halozyme Therapeutics by 3.4% in the third quarter. Artisan Partners Limited Partnership now owns 7,712,874 shares of the biopharmaceutical company’s stock valued at $294,632,000 after purchasing an additional 253,363 shares during the last quarter. TD Asset Management Inc increased its stake in Halozyme Therapeutics by 517.0% in the fourth quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock valued at $73,326,000 after purchasing an additional 1,662,390 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Halozyme Therapeutics by 2.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,736,122 shares of the biopharmaceutical company’s stock valued at $64,167,000 after purchasing an additional 37,763 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,613,113 shares of the biopharmaceutical company’s stock valued at $59,622,000 after purchasing an additional 145,879 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.